PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22084166-5	2012	The FLT-3 inhibitor, SU11657, significantly reduced VEGF secretion in three of six xenograft lines and MV4;11 cells, in conjunction with inhibition of FLT-3 tyrosine phosphorylation.	SU 11657	21-28	fms related receptor tyrosine kinase 3	Homo sapiens	4-9	
22084166-5	2012	The FLT-3 inhibitor, SU11657, significantly reduced VEGF secretion in three of six xenograft lines and MV4;11 cells, in conjunction with inhibition of FLT-3 tyrosine phosphorylation.	SU 11657	21-28	fms related receptor tyrosine kinase 3	Homo sapiens	151-156	
20435347-0	2010	FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657.	SU 11657	124-131	fms related receptor tyrosine kinase 3	Homo sapiens	0-4	
20435347-6	2010	FLT3 and KIT mutated samples were significantly more sensitive to SU11657 than WT KIT and FLT3 samples.	SU 11657	66-73	fms related receptor tyrosine kinase 3	Homo sapiens	0-4	
12515727-0	2003	A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657.	SU 11657	107-114	fms related receptor tyrosine kinase 3	Homo sapiens	20-24	
12515727-9	2003	SU11657, a selective, oral, multitargeted tyrosine kinase inhibitor that targets FLT3, cooperated with all-trans retinoic acid to rapidly cause regression of leukemia.	SU 11657	0-7	fms related receptor tyrosine kinase 3	Homo sapiens	81-85